Logo
x

Search category

Subscribe Now

elicio therapeutics

Elicio Therapeutics Report the First Patient Dosing of ELI-002 7P in P-I/II Trial for KRAS/NRAS Mutated Solid Tumors

Elicio Therapeutics Report the First Patient Dosing of ELI-002 7P in P-I/II Trial for KRAS/NRAS Mutated Solid Tumors

  • April 28, 2023
PharmaShots' Key Highlights of First Quarter 2023

PharmaShots' Key Highlights of First Quarter 2023

  • April 3, 2023
Elicio Therapeutics Entered into a Definitive Merger Agreement with Angion to Advance ELI-002 for Cancer

Elicio Therapeutics Entered into a Definitive Merger Agreement with Angion to Advance ELI-002 for Cancer

  • January 18, 2023
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.